Ex vivo single‐cell profiling of acute myocardial infarction patients reveals disproportionate CD66b+ cell secretion response

IF 6.1 2区 医学 Q1 ENGINEERING, BIOMEDICAL
Kerwin Kwek Zeming, Ri Lu, Elizabeth Lee, Ka‐Wai Cheung, Nicholas W. S. Chew, Kai Lee Woo, Lih Feng Cheow, Jongyoon Han, Shir Lynn Lim
{"title":"Ex vivo single‐cell profiling of acute myocardial infarction patients reveals disproportionate CD66b+ cell secretion response","authors":"Kerwin Kwek Zeming, Ri Lu, Elizabeth Lee, Ka‐Wai Cheung, Nicholas W. S. Chew, Kai Lee Woo, Lih Feng Cheow, Jongyoon Han, Shir Lynn Lim","doi":"10.1002/btm2.70043","DOIUrl":null,"url":null,"abstract":"Acute myocardial infarction (AMI), a leading cause of death globally, triggers complex inflammatory responses critical to patient outcomes. However, rapid tools for profiling immune responses at the single‐cell level are lacking. The integrated Single‐cell Enzyme and Antigen Quantification (iSEAQ) system addresses this gap by enabling high‐throughput, single‐cell analysis of immune cell activity using just 20 μL of blood. This novel tool processes live CD66b and CD3 cells to quantify the secretion of Granzyme B, Neutrophil Elastase, and CD31 within minutes. Longitudinal studies on nine AMI patients revealed that CD66b<jats:sup>+</jats:sup> cells are major contributors (up to 95%) to key inflammatory enzymes, including the unexpected secretion of Granzyme B. iSEAQ achieves unparalleled sensitivity (0.4 fg/cell) and predictive accuracy (&gt;90%) for patient profiling across AMI onset, treatment, and discharge. This innovation provides clinicians with a rapid, precise method to monitor immune responses, unveiling new insights into AMI inflammation and therapy.","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":"43 1","pages":""},"PeriodicalIF":6.1000,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioengineering & Translational Medicine","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1002/btm2.70043","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0

Abstract

Acute myocardial infarction (AMI), a leading cause of death globally, triggers complex inflammatory responses critical to patient outcomes. However, rapid tools for profiling immune responses at the single‐cell level are lacking. The integrated Single‐cell Enzyme and Antigen Quantification (iSEAQ) system addresses this gap by enabling high‐throughput, single‐cell analysis of immune cell activity using just 20 μL of blood. This novel tool processes live CD66b and CD3 cells to quantify the secretion of Granzyme B, Neutrophil Elastase, and CD31 within minutes. Longitudinal studies on nine AMI patients revealed that CD66b+ cells are major contributors (up to 95%) to key inflammatory enzymes, including the unexpected secretion of Granzyme B. iSEAQ achieves unparalleled sensitivity (0.4 fg/cell) and predictive accuracy (>90%) for patient profiling across AMI onset, treatment, and discharge. This innovation provides clinicians with a rapid, precise method to monitor immune responses, unveiling new insights into AMI inflammation and therapy.
急性心肌梗死患者的体外单细胞谱显示不成比例的CD66b+细胞分泌反应
急性心肌梗死(AMI)是全球死亡的主要原因之一,可引发对患者预后至关重要的复杂炎症反应。然而,在单细胞水平上分析免疫反应的快速工具是缺乏的。集成的单细胞酶和抗原定量(iSEAQ)系统通过仅使用20 μL血液就能实现免疫细胞活性的高通量单细胞分析,从而解决了这一空白。这种新型工具处理活的CD66b和CD3细胞,在几分钟内量化颗粒酶B、中性粒细胞弹性酶和CD31的分泌。对9名AMI患者的纵向研究显示,CD66b+细胞是关键炎症酶的主要贡献者(高达95%),包括颗粒酶b的意外分泌。isaq在AMI发病、治疗和出院期间的患者分析方面具有无与伦比的灵敏度(0.4 fg/细胞)和预测准确性(>90%)。这项创新为临床医生提供了一种快速、精确的方法来监测免疫反应,揭示了对AMI炎症和治疗的新见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Bioengineering & Translational Medicine
Bioengineering & Translational Medicine Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
8.40
自引率
4.10%
发文量
150
审稿时长
12 weeks
期刊介绍: Bioengineering & Translational Medicine, an official, peer-reviewed online open-access journal of the American Institute of Chemical Engineers (AIChE) and the Society for Biological Engineering (SBE), focuses on how chemical and biological engineering approaches drive innovative technologies and solutions that impact clinical practice and commercial healthcare products.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信